H.C. Wainwright analyst Ram Selvaraju upgraded CytoDyn Inc (CYDY) to Buy today and set a price target of $1.50. The company’s shares closed on Friday at $0.51.
Selvaraju said:
“Our price target is derived from an estimated market value of the firm at $495M, which includes a discounted cash flow-based asset value of $500M for PRO 140 in the HIV indication alone, with a 15% discount rate, 2% terminal growth rate, 80% probability of success, and excluding $5M debt. Risks include, but are not limited to: (1) failure of PRO 140 in clinical trials; (2) failure of PRO 140 to secure regulatory approval; (3) failure of PRO 140 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) dilution risk.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.6% and a 27.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytoDyn Inc with a $1.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.84 and a one-year low of $0.40. Currently, CytoDyn Inc has an average volume of 256.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin.
